What is the clinical evidence from this study?

Study design: Cohort. Population: Dilated cardiomyopathy (n=91). Intervention: High circulating miR-185 levels vs. Low circulating miR-185 levels. Primary outcome: Cardiovascular mortality at 12 months (p=0.048).

What does this research mean for the field?

High circulating levels of miR-185 are associated with a favorable prognosis, improved cardiac function, and reduced cardiovascular mortality in patients with dilated cardiomyopathy, potentially by repressing B cell function. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 20, 2016Open Access

Circulating miR-185 might be a novel biomarker for clinical outcome in patients with dilated cardiomyopathy

Resultado clave

High circulating miR-185 levels in patients with dilated cardiomyopathy were associated with significantly lower cardiovascular mortality (0% vs 16.7%) and fewer heart failure re-hospitalizations compared to low miR-185 levels over a 1-year follow-up.

Diseño del estudio

Tipo

Cohort (n=91)

Multicéntrico

PICO estructurado

Are high circulating levels of miR-185 associated with improved clinical outcomes and cardiac function in patients with dilated cardiomyopathy?

Población

50 newly diagnosed patients with dilated cardiomyopathy (DCM) based on 1995 WHO/ISFC criteria and 41 age and gender-matched healthy volunteers. Mean age 45, 62% male (DCM group). Excluded: other acute or chronic diseases (tumors, infection, hematopathy, rheumatic diseases) and prior treatment with immunosuppressors or anti-inflammatory drugs. All patients were on standard HF therapy (ACEI/ARBs, beta-blockers, aldosterone antagonist).

Intervención

High circulating plasma miR-185 levels (miR-185high group, n=22)

Comparador

Low circulating plasma miR-185 levels (miR-185low group, n=24)

Resultado

Cardiovascular mortality and total admissions for heart failure re-hospitalizations at 12-month follow-uphard clinical

High circulating levels of miR-185 are associated with improved cardiac function, reduced cardiovascular mortality, and fewer heart failure re-hospitalizations in patients with dilated cardiomyopathy.

Resultado numérico

Tasa de eventos absoluta: 0% vs 16.7%

valor p: p=0.048

Limitaciones

Small sample size
Short duration of follow-up observation

Resumen

B cells contribute to the development of dilated cardiomyopathy (DCM) by inducing myocyte injuries and myocardial fibrosis. Our recent research indicated that microRNA (miR) -185 participated in human B-cell activation. Thus, this study was aimed to explore the relationship between miR-185 and DCM progression. Forty-one healthy volunteers and fifty newly diagnosed DCM patients were enrolled. The levels of plasma miR-185, TNF-α secreting B cells, and anti-heart autoantibody were detected. We found that the mean levels of plasma miR-185 in DCM patients were significantly higher than those in healthy controls. Furthermore, these DCM patients could be divided into miR-185(high) and miR-185(low) groups according to the cluster distribution. During one-year follow-up period, the miR-185(high) group showed apparent improvements in left ventricular ejection fraction, left ventricular end diastolic diameter, and NT-proBNP, accompanied by significant declines in both cardiovascular mortality and total admissions for heart failure re-hospitalizations. In addition, the levels of anti-β1-AR antibody and TNF-α secreting B cells were also reduced in miR-185(high) group. These findings suggested that high miR-185 levels might be associated with a favorable prognosis by repressing B cell function in DCM. The findings of this study need to be confirmed with larger sample size and longer duration of observation.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo